Business Context and Reporting Period
This Form 8-K is a current report filed by Oculus Innovative Sciences, Inc. (not Sonoma Pharmaceuticals, Inc.) on June 24, 2016. The report details a corporate action effective June 24, 2016, at 5:00 pm ET, involving a 1-for-5 reverse stock split of the company's outstanding common stock.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a capital structure change rather than financial performance.
Material Changes
- Reverse Stock Split: Implemented a 1-for-5 reverse stock split of outstanding common stock.
- Authorized Shares: The number of authorized shares of common stock was proportionally decreased from 60 million to 12 million.
- Regulatory Filing: A Certificate of Amendment was filed with the Secretary of State of Delaware to effect these changes.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document notes that the reverse stock split was previously approved by stockholders on June 29, 2015, and the ratio was selected by the Board of Directors on June 2, 2016.
Investor Verification Checklist
- Verify the post-split share count and trading symbol adjustments on the relevant exchange.
- Confirm the reduction of authorized shares from 60 million to 12 million in the updated Certificate of Incorporation.
- Review the attached Exhibit 3.1 (Certificate of Amendment) for specific terms of the amendment.
- Check subsequent filings for any impact on per-share financial metrics due to the reduced share count.